Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Nervous system diseases

First trial of Huntington’s disease drug a success

The first human trial of a drug for Huntington’s disease has shown it to be safe, well-tolerated and successful in lowering the level of huntingtin protein in the nervous system.

The phase I/IIa trial comprised 46 patients with early Huntington’s disease at nine study centres in the UK, Germany and Canada. Each patient received four doses of either the drug, IONIS-HTTRx, or placebo. As the trial progressed, the dose of the drug was increased several times.

The results showed for the first time that IONIS-HTTRx, which is given by injection into the spinal fluid to enable it to reach the brain, significantly lowered the level of the toxic mutant huntingtin protein, the protein known to cause the Huntington’s disease.

Sarah Tabrizi, director of the University College London (UCL) Huntington’s Disease Centre and IONIS-HTTRx global chief investigator said that the results were of ground-breaking importance for Huntington’s disease patients and families.

For the first time, a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well-tolerated.

“The key now is to move quickly to a larger trial to test whether the drug slows disease progression,” she added.

In June 2017, it was announced that all patients in the completed trial would be offered a place in an open-label extension to receive IONIS-HTTRx.

The results of the trial and plans for the ongoing IONIS-HTTRx programme will be presented at forthcoming scientific meetings and prepared for peer-reviewed publication. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20204096

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Huntington s disease wm 17

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.